Serum Cystatin C Concentrations in Patients with Graves’ Ophthalmopathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the concentration of serum cystatin C (CysC) in patients with Graves’ ophthalmopathy (GO) and the usabilityof the serum CysC concentrations in the follow-up of the disease. Methods: Thirty patients with GO and 30 healthy age-matched volunteers were included in this cross-sectional study. GOwas diagnosed based on the European Group on Graves’ Orbitopathy consensus. Serum thyroid-stimulating hormone, freetriiodothyronine, free thyroxine, and CysC concentrations were measured in the participants. The serum CysC concentrationswere compared between patients with GO and controls. Patients with GO were subdivided into hyperthyroid and euthyroidpatients, and their serum CysC concentrations were compared. In addition, the CysC concentrations in hyperthyroid and euthyroidpatients with GO were compared separately with those of healthy subjects. Kruskal-Wallis test and Student’s t-testwere used for statistical evaluation. Results: The mean serum CysC concentrations in GO patients and controls were 1.04 ± 0.36 and 0.74 ± 0.09 mg/L, respectively. There was a statistically significant difference in the serum CysC concentrations between patients with GO and control subjects (p< 0.001). Fifteen patients had hyperthyroid status, and 15 patients had euthyroid status. The mean serum CysC concentrationsin hyperthyroid and euthyroid patients with GO were 1.35 ± 0.22 and 0.72 ± 0.13 mg/L, respectively. Serum CysC concentrationswere significantly higher in hyperthyroid patients than in euthyroid patients (p = 0.001). In addition, hyperthyroid patients hadsignificantly higher serum CysC concentrations than healthy subjects. Among patients with GO, 21 and nine had mild and moderate-to-severe GO, respectively. Active and inactive GO were observed in eight and 22 patients, respectively. Conclusions: The serum CysC concentrations in hyperthyroid patients were higher than those in healthy subjects. Moreover,hyperthyroid patients had higher serum CysC concentrations than euthyroid patients. Further studies with a larger samplesize are needed to confirm these results.
Abstract
Purpose: To evaluate the concentration of serum cystatin C (CysC) in patients with Graves’ ophthalmopathy (GO) and the usabilityof the serum CysC concentrations in the follow-up of the disease. Methods: Thirty patients with GO and 30 healthy age-matched volunteers were included in this cross-sectional study. GOwas diagnosed based on the European Group on Graves’ Orbitopathy consensus. Serum thyroid-stimulating hormone, freetriiodothyronine, free thyroxine, and CysC concentrations were measured in the participants. The serum CysC concentrationswere compared between patients with GO and controls. Patients with GO were subdivided into hyperthyroid and euthyroidpatients, and their serum CysC concentrations were compared. In addition, the CysC concentrations in hyperthyroid and euthyroidpatients with GO were compared separately with those of healthy subjects. Kruskal-Wallis test and Student’s t-testwere used for statistical evaluation. Results: The mean serum CysC concentrations in GO patients and controls were 1.04 ± 0.36 and 0.74 ± 0.09 mg/L, respectively. There was a statistically significant difference in the serum CysC concentrations between patients with GO and control subjects (p< 0.001). Fifteen patients had hyperthyroid status, and 15 patients had euthyroid status. The mean serum CysC concentrationsin hyperthyroid and euthyroid patients with GO were 1.35 ± 0.22 and 0.72 ± 0.13 mg/L, respectively. Serum CysC concentrationswere significantly higher in hyperthyroid patients than in euthyroid patients (p = 0.001). In addition, hyperthyroid patients hadsignificantly higher serum CysC concentrations than healthy subjects. Among patients with GO, 21 and nine had mild and moderate-to-severe GO, respectively. Active and inactive GO were observed in eight and 22 patients, respectively. Conclusions: The serum CysC concentrations in hyperthyroid patients were higher than those in healthy subjects. Moreover,hyperthyroid patients had higher serum CysC concentrations than euthyroid patients. Further studies with a larger samplesize are needed to confirm these results.
참고문헌 (21)
- Jinguji M, "Thymic involution after radioiodine therapy for Graves disease : relationships with serum thyroid hormones and TRAb", J Endocr Soc, 1, pp.852~860 (2017)
- Kamboj A, "Ophthalmic manifestations of endocrine disorders-endocrinology and the eye", Transl Pediatr, 6, pp.286~299 (2017)
- Xiong H, "Genetic associations of the thyroid stimulating hormone receptor gene with Graves diseases and Graves ophthalmopathy : a meta-analysis", Sci Rep, 6, pp.30356~ (2016)
- Xia N, "Simultaneous induction of Graves’ hyperthyroidism and Graves’ ophthalmopathy by TSHR genetic immunization in BALB", c mice, 2017, pp.12, e0174260~
- Xu L, "Thickness of extraocular muscle and orbital fat in MRI predicts response to glucocorticoid therapy in Graves’ ophthalmopathy", Int J Endocrinol, 2017, pp.3196059~ (2017)
- Li YJ, "Clinical outcomes of graves’ophthalmopathy treated with intensity modulated radiation therapy", Radiat Oncol, 12, pp.171~ (2017)
- Khatavi F, "A promising modified procedure for upper eyelid retraction-associated Graves’ ophthalmopathy : transconjunctival lateral levator aponeurectomy", Med Hypothesis Discov Innov Ophthalmol, 6, pp.44~48 (2017)
- Hao HT, "Treatment of Graves’ophthalmopathy with an in-house Phosphorus-32 source : initial clinical observations", Exp Ther Med, 14, pp.2795~2800 (2017)
- Sabini E, "Does Graves’ orbitopathy ever disappear? : answers to an old question", Eur Thyroid J, 6, pp.263~270 (2017)
- De Souza V, "Creatinine-versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis", Hepatology, 59, pp.1522~1531 (2014)
- Fricker M, "Impact of thyroid dysfunction on serum cystatin C", Kidney Int, 63, pp.1944~1947 (2003)
- Ozden TA, "Effect of hypo-and euthyroid status on serum cystatin C levels", J Clin Res Pediatr Endocrinol, 2, pp.155~158 (2010)
- Kotajima N, "Influence of thyroid hormones and transforming growth factor-β1 on cystatin C concentrations", J Int Med Res, 38, pp.1365~1373 (2010)
- Bartalena L, "The 2016 European Thyroid Association", European Group on Graves’Orbitopathy Guidelines for the Management of Graves’Orbitopathy, 2016, pp.5, 9~26
- Jayagopal V, "Paradoxical changes in cystatin C and serum creatinine in patients with hypo-and hyperthyroidism", Clin Chem, 49, pp.680~681 (2003)
- Den Hollander JG, "Is cystatin C a marker of glomerular filtration rate in thyroid dysfunction?", Clin Chem, 49, pp.1558~1559 (2003)
- Schmid C, "Triiodothyronine stimulates cystatin C production in bone cells", Biochem Biophys Res Commun, 419, pp.425~430 (2012)
- Wiesli P, "Serum cystatin C is sensitive to small changes in thyroid function", Clin Chim Acta, 338, pp.87~90 (2003)
- Ye Y, "Impact of thyroid function on serum cystatin C and estimated glomerular filtration rate : a cross-sectional study", Endocr Pract, 19, pp.397~403 (2013)
- Cimerman N, "Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients", Clin Chim Acta, 300, pp.83~95 (2000)
- Risch L, "Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients", Clin Chem, 47, pp.2055~2059 (2001)